







|  |                               |   |   |                         |                          |  |  |   |
|--|-------------------------------|---|---|-------------------------|--------------------------|--|--|---|
|   |                               | <b>TRANSMITTAL LETTER</b><br>(General - Patent Pending) |   | Docket No.<br>22037B/US |                          |  |  |   |
| Re Application Of: Allerton et al.   |                               |   |   |                         |                          |  |  |   |
| Application No.<br>10/812,143  | Filing Date<br>March 29, 2004 | Examiner<br>Stockton                                    | Customer No.<br>26648   | Group Art Unit<br>1626  | Confirmation No.<br>3239 |  |  |   |
| Title: 3-(IMIDAZOLYL)-2-ALKOXYPROPANOIC ACIDS  |                               |   |   |                         |                          |  |  |   |
| <u>COMMISSIONER FOR PATENTS:</u>   |                               |   |   |                         |                          |  |  |   |
| Transmitted herewith is:<br><br>Reply to Office Action; Terminal Disclaimer (\$130.00); Itemized Postcard.   |                               |   |   |                         |                          |  |  |   |
| in the above identified application.   |                               |   |   |                         |                          |  |  |   |
| <input type="checkbox"/> No additional fee is required.  |                               |   |   |                         |                          |  |  |   |
| <input type="checkbox"/> A check in the amount of _____ is attached.   |                               |   |   |                         |                          |  |  |   |
| <input checked="" type="checkbox"/> The Director is hereby authorized to charge and credit Deposit Account No. 19-1025 as described below.   |                               |   |   |                         |                          |  |  |   |
| <input checked="" type="checkbox"/> Charge the amount of \$130.00  |                               |   |   |                         |                          |  |  |   |
| <input checked="" type="checkbox"/> Credit any overpayment.  |                               |   |   |                         |                          |  |  |   |
| <input checked="" type="checkbox"/> Charge any additional fee required.  |                               |   |   |                         |                          |  |  |   |
| <input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.  |                               |   |   |                         |                          |  |  |   |
| <b>WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</b>  |                               |   |   |                         |                          |  |  |   |
| <br>Signature   |                               |   | Dated: April 15, 2005   |                         |                          |  |  |   |
| Daniel S. Kasten, Reg. No. 45,363<br>Pharmacia Corporation of Pfizer Inc.<br>P.O. Box 1027<br>Chesterfield, Missouri 63006<br>314.274.5218   |                               |   | <table border="1"><tr><td>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on<br/>April 15, 2005<br/>(Date)</td></tr><tr><td><br/>Signature of Person Mailing Correspondence</td></tr><tr><td>Linda K. Cooper<br/>Typed or Printed Name of Person Mailing Correspondence</td></tr></table> |                         |                          | I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on<br>April 15, 2005<br>(Date) | <br>Signature of Person Mailing Correspondence | Linda K. Cooper<br>Typed or Printed Name of Person Mailing Correspondence |
| I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on<br>April 15, 2005<br>(Date) |                               |   |   |                         |                          |  |  |   |
| <br>Signature of Person Mailing Correspondence   |                               |   |   |                         |                          |  |  |   |
| Linda K. Cooper<br>Typed or Printed Name of Person Mailing Correspondence  |                               |   |   |                         |                          |  |  |   |
| cc:  |                               |   |   |                         |                          |  |  |   |



PATENT

PC22037B-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Allerton et al.

GROUP ART UNIT: 1626

SERIAL NUMBER: 10/812,143


EXAMINER: Stockton, Laura Lynne

FILED: 03/29/04

TITLE: 3-(Imidazolyl)-2-Alkoxypropanoic Acids

I hereby certify that this correspondence is being  
deposited with the United States Postal Service as  
First Class Mail in an envelope addressed to:  
Commissioner for Patents P.O. Box 1450  
Alexandria, VA 22313-1450 on April 15, 2005

Linda Cooper

 Date: 4/15/2005

REPLY TO OFFICE ACTION

Commissioner of Patents  
Alexandria, VA 22313-1450

Sir:

In response to the Office Action dated February 11, 2005, please  
enter the following remarks.